Recommendations for screening and detection of connective tissue disease–associated pulmonary arterial hypertension
D Khanna, H Gladue, R Channick… - Arthritis & …, 2013 - Wiley Online Library
Objective Pulmonary arterial hypertension (PAH) affects up to 15% of patients with
connective tissue diseases (CTDs). Previous recommendations developed as part of larger …
connective tissue diseases (CTDs). Previous recommendations developed as part of larger …
[HTML][HTML] Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme
K Morrisroe, W Stevens, J Sahhar, C Rabusa… - Arthritis research & …, 2017 - Springer
Background Pulmonary arterial hypertension (PAH) is the leading cause of death in
systemic sclerosis (SSc). Annual screening with echocardiogram (ECHO) is recommended …
systemic sclerosis (SSc). Annual screening with echocardiogram (ECHO) is recommended …
Combination of echocardiographic and pulmonary function test measures improves sensitivity for diagnosis of systemic sclerosis-associated pulmonary arterial …
H Gladue, V Steen, Y Allanore, R Saggar… - The Journal of …, 2013 - jrheum.org
Objective. To evaluate routinely collected non-invasive tests from 2 systemic sclerosis (SSc)
cohorts to determine their predictive value alone and in combination versus right heart …
cohorts to determine their predictive value alone and in combination versus right heart …
Cost savings with a new screening algorithm for pulmonary arterial hypertension in systemic sclerosis
A Quinlivan, V Thakkar, W Stevens… - Internal medicine …, 2015 - Wiley Online Library
Background Screening for pulmonary arterial hypertension (PAH) in systemic sclerosis
(SSc) is now standard care in this disease. The existing A ustralian S cleroderma I nterest G …
(SSc) is now standard care in this disease. The existing A ustralian S cleroderma I nterest G …